IGM-2644

· IGM Biosciences, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IGM-2644, covering 2024-08-01 to 2024-08-01. Get the full timeline:

Most recent: Clinical Trial Update: Evaluation of IGM-2644 in Adults With Relapsed and/or Refractory Multiple Myeloma [Phase 1]